Physician

Wayne D Ormsby, M.D.

According to 2025 Medicare claims, Wayne Ormsby, M.D. (NPI: 1851417158) practices medical oncology in the Ogden, UT market, with the plurality of this provider's patient population coming from Davis, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84010-8924.

Ormsby's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 299 traditional Medicare patients, billed 99,283 HCPCS/CPT codes, and received $1,888,157 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 979 prescription claims across 188 beneficiaries totaling $3,502,579 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 32 claims. Open Payments data shows 9 records totaling $194. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $930,603 and ending at $1,888,157. Concurrently, Part D prescription costs have risen steadily, from $1,574,416 to $3,502,579. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	350	83,439	$930,603
2016	267	42,652	$567,261
2017	369	60,903	$1,465,377
2018	435	96,219	$1,836,467
2019	397	90,637	$1,970,742
2020	360	71,477	$1,627,725
2021	296	60,707	$1,213,093
2022	294	46,003	$926,464
2023	281	70,255	$1,190,655
2024	299	99,283	$1,888,157

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	187	1,005	$1,574,416
2016	142	558	$793,927
2017	103	463	$653,832
2018	157	854	$2,329,507
2019	176	1,064	$3,019,364
2020	168	1,061	$2,276,244
2021	152	816	$1,911,873
2022	148	833	$2,771,650
2023	175	938	$3,404,013
2024	188	979	$3,502,579

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	45	$16,277
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	49	$4,314
2019	N/R	33	$433
2020	N/R	32	$411
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	381	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	148	213	$59
80053	Blood test, comprehensive group of blood chemicals	185	529	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	226	783	$8
83615	Lactate dehydrogenase (enzyme) level	84	204	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	48	1,344	$851,160
Brukinsa	Zanubrutinib	39	1,170	$405,010
Calquence	Acalabrutinib Maleate	27	810	$294,160
Imbruvica	Ibrutinib	14	392	$202,056
Xtandi	Enzalutamide	13	390	$174,501

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$194	Genmab U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Wayne D. Ormsby, M.D.?

Tedicare shows public-source Medicare data for Wayne D. Ormsby, M.D. (NPI 1851417158), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wayne D. Ormsby, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Wayne D. Ormsby, M.D.?

Wayne D. Ormsby, M.D. is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Wayne D. Ormsby, M.D. have Open Payments data?

Wayne D. Ormsby, M.D. has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.